Pamplona

• A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder. Pending
  2025-524488-18-00 4 Muscle-invasive Bladder Cancer
• A Research Study Testing New Cancer Medicines Used Alone or Together to Treat Solid Tumors Pending
  2025-524623-50-00 9 Solid Tumors
• Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD) Pending
  2025-525068-13-00 4 Chronic Kidney Disease
• A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-523815-12-00 5 2026-07-06 Relapsed or Refractory Multiple Myeloma
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Recruiting
  2025-520565-51-00 5 2026-06-23 small cell lung cancer
• Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES) Recruiting
  2025-521709-42-00 5 2026-06-23 Allergic rhinoconjunctivitis with or without asthma due to clinically
• Grass Immunotherapy for Rhinitis and Asthma (GIRA) Recruiting
  2025-521736-10-00 5 2026-06-23 Allergic rhinoconjunctivitis with or without controlled asthma
• Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOT … Recruiting
  2023-508863-59-01 4 2026-06-17 Resectable Hepatocellular Carcinoma
• Elranatamab Post Trial Access Study for Participants With Multiple Myeloma Recruiting
  2023-505200-33-00 5 2026-06-15 Multiple myeloma
• A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of IM-101 in Adult Participants with Generalized Myasthenia Gr … Recruiting
  2025-522406-20-00 9 2026-06-15 Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304) Recruiting
  2025-523495-23-00 5 2026-06-09 Resected Pancreatic Ductal Adenocarcinoma (PDAC)
• A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older with Locally Advanced or Metastatic … Recruiting
  2024-518871-74-00 4 2026-06-08 Locally Advanced or Metastatic Solid Tumours that harbour MET Amplific
• A Basket Trial of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies Recruiting
  2025-523774-16-00 9 2026-06-03 Advanced malignancies
• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Recruiting
  2024-519994-20-00 5 2026-06-01 Agitation Associated with Alzheimer’s Disease
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Recruiting
  2025-521590-13-00 5 2026-05-28 Moderately to Severely Active Crohn’s Disease
• An Efficacy and Safety Study of Clemizole HCl in Patients with Lennox-Gastaut Syndrome Recruiting
  2025-522552-20-00 5 2026-05-28 Lennox-Gastaut Syndrome
• INTRATUMORAL DNX-2401 ADMINISTRATION FOR RECURRENT AND REFRACTORY HIGH GRADE BRAIN TUMORS IN PEDIATRIC AND YOUNG ADULT PATIENTS Recruiting
  2024-515009-24-00 4 2026-05-08 High grade malignant brain neoplasm
• Efficacy and safety study of intravenous brincidofovir compared to intravenous cidofovir for the treatment of adenovirus infection in childr … Recruiting
  2025-521903-28-00 5 2026-05-06 Adenovirus viremia
• A study to assess the effects of zigakibart on IgA nephropathy. Recruiting
  2024-519699-24-00 4 2026-04-23 IgA nephropathy
• A study for adolescents who are depressed and thinking of suicide Recruiting
  2024-518615-19-00 5 2026-04-22 Major Depressive Disorder
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R … Recruiting
  2024-519818-31-01 5 2026-04-10 Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresec
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)

Showing 49–72 of 829 trials